Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Share-based Compensation (2018 - 2025)

Historic Share-based Compensation for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to $5.7 million.

  • Arcturus Therapeutics Holdings' Share-based Compensation fell 3965.03% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.6 million, marking a year-over-year decrease of 2709.15%. This contributed to the annual value of $38.0 million for FY2024, which is 963.66% up from last year.
  • Latest data reveals that Arcturus Therapeutics Holdings reported Share-based Compensation of $5.7 million as of Q3 2025, which was down 3965.03% from $6.2 million recorded in Q2 2025.
  • Arcturus Therapeutics Holdings' 5-year Share-based Compensation high stood at $10.1 million for Q1 2024, and its period low was $5.7 million during Q3 2025.
  • Moreover, its 5-year median value for Share-based Compensation was $7.5 million (2021), whereas its average is $7.9 million.
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' Share-based Compensation soared by 72296.82% in 2021, and later crashed by 3965.03% in 2025.
  • Arcturus Therapeutics Holdings' Share-based Compensation (Quarter) stood at $7.5 million in 2021, then dropped by 13.14% to $6.5 million in 2022, then skyrocketed by 34.99% to $8.8 million in 2023, then grew by 1.91% to $9.0 million in 2024, then tumbled by 36.22% to $5.7 million in 2025.
  • Its last three reported values are $5.7 million in Q3 2025, $6.2 million for Q2 2025, and $6.7 million during Q1 2025.